SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer

SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer

2026.01.13
In patients with HR-positive/HER2-positive early breast cancer, adjuvant anti-HER2 therapy constitutes the cornerstone of systemic treatment. However, robust high-level evidence has long been lacking to guide the choice between aromatase inhibitors (AIs) and tamoxifen (SERMs) for adjuvant endocrine therapy in this population.
SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

2026.01.13
De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated that ctDNA clearance is strongly associated with pathological complete response (pCR), while baseline ctDNA positivity predicts poorer outcomes.
Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

2026.01.12
The 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Annual Academic Meeting on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were recently held successfully in Chengdu, Sichuan. Centered on urologic and male genitourinary malignancies, the conference emphasized timeliness and diversity, combining a global perspective with Chinese clinical realities to build a high-level platform for academic exchange and innovation in urologic oncology. During the meeting, Oncology Frontier – Urology Frontier invited Academician Xu Zhang from The Third Medical Center, Chinese PLA General Hospital to share his insights on China’s distinctive achievements in minimally invasive surgery, recent advances in systemic therapy, and their clinical value.
Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology

Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology

2026.01.12
From VEGF-targeted agents to immune-based combinations and novel HIF-2α inhibitors, the expanding therapeutic arsenal for renal cell carcinoma (RCC) has significantly prolonged patient survival. At the same time, it has posed a more demanding challenge for clinicians: how to tailor the optimal treatment for each individual patient and truly achieve precision medicine.